Rare
lephants
Knowledge
Value Investing
What is Value Investing?
What Is a Moat?
Intangible Assets
Cost Advantage
Pricing Power
Network Effect
Switching Costs
Efficient Scale
Intrinsic Value
Margin of Safety
Circle of Competence
Mr. Market
ROIC
Financial Statements
Income Statement
High Gross Margins
R&D Spending
Sales & Marketing
Net Margin
Balance Sheet
Long-Term Debt
Float
Receivables/Payables
Derivatives
Cash Flow Statement
Free Cash Flow
Shareholder Returns
Cap Ex
Stock-Based Compensation
Berkshire Hathaway Lessons
The Four Criteria — 1977
Rare Fast-Moving Elephants — 1987
Mr. Market — 1987
Wonderful Companies at Fair Prices — 1989
Risk Isn’t Volatility — 1993
Circle of Competence — 1996
Swimming Naked — 2001
“Price Is What You Pay...” — 2008
Famous Value Investors
Benjamin Graham
Warren Buffett
Charlie Munger
Phil Fisher
Peter Lynch
Howard Marks
Screener
Toggle theme
Royalty Pharma plc
RPRX
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Total Cash from Operations:
$2.40B
Line Item
Value
% of Total
Other Investing
$1.87B
77.8%
Net Cash Flow
$532.4M
22.2%
